Articles |
From the Department of Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, the Netherlands (J.A.K., A.E., J.J.P.K.); Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, the Netherlands (A.F.H.S.); and the Atherosclerosis Specialty Laboratory, Department of Pathology and Laboratory Medicine, St Paul's Hospital and University of British Columbia, Vancouver Canada (J.S.H., P.H.P.).
Correspondence to P. Haydn Pritchard, PhD, Healthy Heart Program, St Paul's Hospital, 1081 Burrard St, Vancouver, British Columbia, Canada V6Z 1Y6. E-mail hpcy@unixg.ubc.ca.
Abstract A 53-year-old man with a severely reduced HDL cholesterol level, dense corneal opacities, normal renal function, and premature coronary artery disease was investigated together with 16 members of his family. The proband was diagnosed with fish eye disease. As in previously reported patients with fish eye disease, the endogenous plasma cholesterol esterification rate was near normal, yet lecithin:cholesterol acyltransferase (LCAT) activity was almost absent when measured with exogenous HDL analogues used as substrate. Direct sequencing of the LCAT gene revealed two novel missense mutations in exon 1 and exon 4, resulting in the substitution of Pro10 with Gln (P10Q) and Arg135 with Gln (R135Q), respectively. Both missense mutations were located on different alleles. Genetic analysis by polymerase chain reaction revealed 4 carriers of the P10Q and 3 carriers of the R135Q defect. Functional assessment of both missense mutations revealed that when exogenous HDL analogues were used as substrate, the specific activity of rLCATP10Q was 18% of wild type (WT); however, when LDL was used as substrate, the activity was 146% of WT. By contrast, rLCATR135Q was inactive against both substrates. Thus, we conclude that the LCATR135D mutation is causative for complete LCAT deficiency and that the clinical phenotype of fish eye disease seen in this patient is due to the Pro10 mutation. The presence of premature coronary artery disease in the absence of other risk factors in this new case of fish eye disease raises questions regarding the risk of atherosclerosis, which has previously been reported to be nonexistent.
Key Words: HDL deficiency lecithin:cholesterol acyltransferase fish eye disease corneal opacities
This article has been cited by other articles:
![]() |
G. K. Hovingh, B. A. Hutten, A. G. Holleboom, W. Petersen, P. Rol, A. Stalenhoef, A. H. Zwinderman, E. de Groot, J. J.P. Kastelein MD, and J. A. Kuivenhoven Compromised LCAT Function Is Associated With Increased Atherosclerosis Circulation, August 9, 2005; 112(6): 879 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Forte, G. Subbanagounder, J. A. Berliner, P. J. Blanche, A. O. Clermont, Z. Jia, M. N. Oda, R. M. Krauss, and J. K. Bielicki Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice J. Lipid Res., March 1, 2002; 43(3): 477 - 485. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Sirtori, L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, J. Johansson, M. Salvetti, C. Monteduro, R. Zulli, M. L. Muiesan, et al. Cardiovascular Status of Carriers of the Apolipoprotein A-IMilano Mutant : The Limone sul Garda Study Circulation, April 17, 2001; 103(15): 1949 - 1954. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Forte, M. N. Oda, L. Knoff, B. Frei, J. Suh, J. A. K. Harmony, W. D. Stuart, E. M. Rubin, and D. S. Ng Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration J. Lipid Res., July 1, 1999; 40(7): 1276 - 1283. [Abstract] [Full Text] |
||||
![]() |
J. K. Bielicki and T. M. Forte Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity J. Lipid Res., May 1, 1999; 40(5): 948 - 954. [Abstract] [Full Text] |
||||
![]() |
F. Peelman, J-L. Verschelde, B. Vanloo, C. Ampe, C. Labeur, J. Tavernier, J. Vandekerckhove, and M. Rosseneu Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity J. Lipid Res., January 1, 1999; 40(1): 59 - 69. [Abstract] [Full Text] |
||||
![]() |
F. Blanco-Vaca, S.-J. Qu, C. Fiol, H.-Z. Fan, Q. Pao, A. Marzal-Casacuberta, J. J. Albers, I. Hurtado, V. Gracia, X. Pinto, et al. Molecular Basis of Fish-Eye Disease in a Patient From Spain : Characterization of a Novel Mutation in the LCAT Gene and Lipid Analysis of the Cornea Arterioscler Thromb Vasc Biol, July 1, 1997; 17(7): 1382 - 1391. [Abstract] [Full Text] |
||||
![]() |
G. Lambert, N. Sakai, B. L. Vaisman, E. B. Neufeld, B. Marteyn, C.-C. Chan, B. Paigen, E. Lupia, A. Thomas, L. J. Striker, et al. Analysis of Glomerulosclerosis and Atherosclerosis in Lecithin Cholesterol Acyltransferase-deficient Mice J. Biol. Chem., April 27, 2001; 276(18): 15090 - 15098. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |